Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Viking Therapeutics has initiated a ~280-patient phase 2a study of oral VK2735, with management guiding for a result in H2'25. Previous trials of VK2735 have enrolled ahead of schedule ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.